

## SUBSTANTIAL SHAREHOLDERS

### SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the Share Subdivision, Conversion and [REDACTED] and assuming the Share Options outstanding as at the Latest Practicable Date, the following persons will have interests or short positions in our Shares or our underlying Shares which would fall to be disclosed to us under the provisions of Divisions 2 and 3 of Part XV of the SFO, or, will be, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company or any other member of our Group:

Name of Shareholder	Capacity/ Nature of Interest	Number of Shares as of the Latest Practicable Date <sup>(1)</sup>	Approximate percentage of interest in our Company upon the completion of the [REDACTED] (assuming the [REDACTED] is not exercised)	Approximate percentage of interest in our Company upon the completion of the [REDACTED]
CTX Pharma <sup>(2)</sup>	Beneficial interest	2,604,238	[REDACTED]	[REDACTED]
Dr. Xue <sup>(2)(3)(4)</sup>	Interest in controlled corporation	2,604,238	[REDACTED]	[REDACTED]
	Founder of a discretionary trust	1,500,000	[REDACTED]	[REDACTED]
	Beneficial interest	73,305	[REDACTED]	[REDACTED]
WuXi AppTec <sup>(5)</sup>	Interest in controlled corporation	4,034,696	[REDACTED]	[REDACTED]
RA Capital Management, L.P. <sup>(6)</sup>	Interest in controlled corporation	3,654,959	[REDACTED]	[REDACTED]
Qiming Corporate GP IV, Ltd. <sup>(7)</sup>	Interest in controlled corporation	3,282,933	[REDACTED]	[REDACTED]
Qiming Venture Partners IV, L.P. <sup>(7)</sup>	Beneficial interest	3,182,449	[REDACTED]	[REDACTED]

*Notes:*

- (1) The number of Shares held assuming that all of the Preferred Shares have been converted into the Shares on a one-to-one basis. The number of shares held are subject to adjustments as a result of the Share Subdivision.
- (2) CTX Pharma is an exempted company with limited liability incorporated in the British Virgin Islands and holds 2,604,238 Shares in our Company. CTX Pharma is wholly-owned by Dr. Xue. Pursuant to a voting rights proxy agreement dated February 9, 2020, each of Xiangyun Holdings Limited, Apollo China Holdings Limited, Sea&Sky Holdings Limited, Clear Stone Holdings Limited, Hongweix Holdings Limited, Medkelvin Holdings Limited, Chengzhang Holdings Limited, Dingkai Holdings Limited, Merrifield Holdings Limited and Flemingddf Holdings Limited (the “Entrusters”), who in aggregate hold 2,790,416 Shares in our Company, voluntarily entrusted all of the voting rights of their Shares directly held in our Company to CTX Pharma. Accordingly, each of CTX Pharma and Dr. Xue is deemed interested in the Shares held by the Entrusters. Such voting rights proxy agreement will terminate upon [REDACTED].

---

## SUBSTANTIAL SHAREHOLDERS

---

- (3) Dr. Xue beneficially holds 73,305 Shares of our Company under his own name.
- (4) 1,500,000 Shares of our Company are held by the Family Trust. Under the terms of the Family Trust, Dr. Xu has the power to exercise all the voting rights attached to the Shares of our Company. Accordingly, Dr. Xue is deemed interested in the Shares held by the Family Trust.
- (5) WuXi AppTec (HongKong) Limited, company incorporated in Hong Kong on March 26, 2012 holding 2,055,486 Shares of our Company, is a wholly-owned subsidiary of WuXi AppTec. Moreover, WuXi PharmaTech Healthcare Fund I L.P. is an exempted limited partnership established in the Cayman Islands directly holding 1,979,210 Shares in our Company. All limited partnership interests of WuXi PharmaTech Healthcare Fund I L.P. are held by Wuxi Apptec and the general partner of WuXi PharmaTech Healthcare Fund I L.P. is a wholly-owned subsidiary of WuXi AppTec. Accordingly, Wuxi Apptec is deemed interested in the Shares held by each of WuXi AppTec (HongKong) Limited and WuXi PharmaTech Healthcare Fund I L.P..
- (6) RA Capital Management, L.P., a limited partnership formed in Delaware, United States, serves as investment manager of RA Capital Healthcare Fund, L.P., an exempted limited partnership established in Delaware, United States, directly holding 2,349,914 Shares in our Company, RA Capital Nexus Fund, L.P., an exempted limited partnership established in the Delaware, United States, directly holding 913,740 Shares in our Company, and Blackwell Partners LLC – Series A, a series limited liability company incorporated in Delaware, United States, holds 391,305 Shares in our Company. The general partner of RA Capital Healthcare Fund, LP is RA Capital Healthcare Fund GP, LLC and the general partner of RA Capital Nexus Fund, LP is RA Capital Nexus Fund GP, LLC. Each of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P. is an affiliate of RA Capital Management, L.P.. Accordingly, RA Capital Management, L.P. is deemed interested in the Shares held by each of RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P. and Blackwell Partners LLC.
- (7) Qiming Venture Partners IV, L.P. and Qiming Managing Directors Fund IV, L.P. are venture capital funds operated under Qiming Venture Partners and registered as exempted limited partnerships in the Cayman Islands. Qiming GP IV, L.P. is the general partner of Qiming Venture Partners IV, L.P., and Qiming Corporate GP IV, Ltd. is the general partner of Qiming GP IV, L.P. Accordingly, each of Qiming GP IV, L.P. and Qiming Corporate GP IV, Ltd. is deemed to be interested in the Shares held by Qiming Venture Partners IV, L.P. Moreover, Qiming Managing Directors Fund IV, L.P. holds 100,484 Shares of our Company. Qiming Corporate GP IV, Ltd. is the general partner of Qiming Managing Directors Fund IV, L.P. and is deemed to be interested in the Shares held by Qiming Managing Directors Fund IV, L.P..

Except as disclosed above, our Directors are not aware of any other person who will, immediately following the completion of the [REDACTED] (assuming the Share Options outstanding as at the Latest Practicable Date and the [REDACTED] are not exercised), have any interest and/or short positions in the Shares or underlying shares of our Company which would fall to be disclosed to us pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, who are, directly or indirectly, interested in 5% or more of the nominal value of any class of our share capital carrying rights to vote in all circumstances at general meetings of our Company. Our Directors are not aware of any arrangement which may at a subsequent date result in a change of control of our Company or any other member of our Group.